Dual Dopamine/Serotonin Releasers: Potential Treatment Agents for Stimulant Addiction

Experimental and Clinical Psychopharmacology

Volumn 16, Issue 6, 2008, Pages 458-474

  Rothman, Richard B ^a   Blough, Bruce E ^b   Baumann, Michael H ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b RTI INTERNATIONAL   (United States)

Author keywords

alcohol; amphetamine; cocaine; dopamine; serotonin; transporter

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 3 FLUOROAMPHETAMINE; 4 METHYLAMPHETAMINE; 5 HYDROXYINDOLEACETIC ACID; ALCOHOL; AMPHETAMINE; CHLORPHENTERMINE; COCAINE; DOPAMINE; ERGOTAMINE; FENFLURAMINE; FLUOXETINE; METHAMPHETAMINE; METHYLERGOMETRINE; METHYSERGIDE; NAPHTHYLISOPROPYLAMINE; NORFENFLURAMINE; NORFLUOXETINE; PAL 287; PAL 313; PAL 353; PHENTERMINE; PSYCHOSTIMULANT AGENT; SEROTONIN; SEROTONIN 2 RECEPTOR; TRAZODONE; UNCLASSIFIED DRUG;

ALCOHOL ABSTINENCE; ALCOHOL ABUSE; ANHEDONIA; COCAINE DEPENDENCE; DEPRESSION; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DRUG DEPENDENCE TREATMENT; DRUG MECHANISM; DRUG MEGADOSE; DRUG SELF ADMINISTRATION; DRUG STRUCTURE; HUMAN; IMPULSIVENESS; LOCOMOTION; NEUROTOXICITY; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PARKINSONISM; PLACE PREFERENCE; PULMONARY HYPERTENSION; REINFORCEMENT; REVIEW; SEROTONIN RELEASE; SUBSTANCE ABUSE; SYMPTOMATOLOGY; VALVULAR HEART DISEASE; WITHDRAWAL SYNDROME;

ANIMALS; BEHAVIOR, ADDICTIVE; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE-RELATED DISORDERS; DOPAMINE; HUMANS; SEROTONIN; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS;

EID: 57949089064     PISSN: 10641297     EISSN: None     Source Type: Journal    
DOI: 10.1037/a0014103     Document Type: Review

References (175)

1. Abenhaim L., Moride Y., Brenot F., Rich S., Benichou J., Kurz X., et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group [see comments]. New England Journal of Medicine 335 (1996) 609-616
2. Alex K.D., and Pehek E.A. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacology and Therapeutics 113 (2007) 296-320
3. Alexander M., Rothman R.B., Baumann M.H., Endres C.J., Brasic J.R., and Wong D.F. Noradrenergic and dopaminergic effects of (+)-amphetamine-like stimulants in the baboon Papio anubis. Synapse 56 (2005) 94-99
4. Alim T.N., Rosse R.B., Vocci Jr. F.J., Lindquist T., and Deutsch S.I. Diethylpropion pharmacotherapeutic adjuvant therapy for inpatient treatment of cocaine dependence: A test of the cocaine-agonist hypothesis. Clinical Neuropharmacology 18 (1995) 183-195
5. Amara S.G., and Kuhar M.J. Neurotransmitter transporters: Recent progress. Annual Review of Neuroscience 16 (1993) 73-93
6. Amara S.G., and Sonders M.S. Neurotransmitter transporters as molecular targets for addictive drugs. Drug and Alcohol Dependence 51 (1998) 87-96
7. Anonymous. Increasing morbidity and mortality associated with abuse of methamphetamine-United States, 1991-1994. MMWR Morbidity and Mortality Weekly Report 44 (1995) 882-886
8. Arnsten A.F. Stimulants: Therapeutic actions in ADHD. Neuropsychopharmacology 31 (2006) 2376-2383
9. Artigas F., Sarrias M.J., Martinez E., Gelpi E., Alvarez E., and Udina C. Increased plasma free serotonin but unchanged platelet serotonin in bipolar patients treated chronically with lithium. Psychopharmacology (Berl) 99 (1989) 328-332
10. Bana D.S., MacNeal P.S., LeCompte P.M., Shah Y., and Graham J.R. Cardiac murmurs and endocardial fibrosis associated with methysergide therapy. American Heart Journal 88 (1974) 640-655
11. Barnes N.M., and Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 38 (1999) 1083-1152
12. Baumann M.H., Ayestas M.A., Dersch C.M., Brockington A., Rice K.C., and Rothman R.B. Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: Therapeutic implications. Synapse 36 (2000) 102-113
13. Baumann M.H., Ayestas M.A., Dersch C.M., and Rothman R.B. 1-(m-Chlorophenyl)piperazine (mCPP) dissociates in vivo serotonin release from long-term serotonin depletion in rat brain. Neuropsychopharmacology 24 (2001) 492-501
14. Baumann M.H., Becketts K.M., and Rothman R.B. Evidence for alterations in presynaptic serotonergic function during withdrawal from chronic cocaine in rats. European Journal of Pharmacology 282 (1995) 87-93
15. Baumann M.H., Mash D.C., and Staley J.K. The serotonin agonist m-chlorophenylpiperazine (mCPP) binds to serotonin transporter sites in human brain. Neuroreport 6 (1995) 2150-2152
16. Baumann M.H., and Rothman R.B. Alterations in serotonergic responsiveness during cocaine withdrawal in rats: Similarities to major depression in humans. Biological Psychiatry 44 (1998) 578-591
17. Baumann M.H., and Rothman R.B. Serotonergic dysfunction during cocaine withdrawal: Implications for cocaine-induced depression. In: Karch S.B. (Ed). Drug abuse handbook (1998), CRC Press, Boca Raton, FL 463-484
18. Baumann M.H., Rutter J.J., and Auerbach S.B. Intravenous administration of the serotonin agonist m-chlorophenylpiperazine (mCPP) increases extracellular serotonin in the diencephalon of awake rats. Neuropharmacology 32 (1993) 1381-1386
19. Blakely R.D., Defelice L.J., and Galli A. Biogenic amine neurotransmitter transporters: Just when you thought you knew them. Physiology (Bethesda) 20 (2005) 225-231
20. Brauer L.H., Johanson C.E., Schuster C.R., Rothman R.B., and de Wit H. Evaluation of phentermine and fenfluramine, alone and in combination, in normal, healthy volunteers. Neuropsychopharmacology 14 (1996) 233-241
21. Bredberg U., Eyjolfsdottir G.S., Paalzow L., Tfelt-Hansen P., and Tfelt-Hansen V. Pharmacokinetics of methysergide and its metabolite methylergometrine in man. European Journal of Clinical Pharmacology 30 (1986) 75-77
22. Bubar M.J., and Cunningham K.A. Serotonin 5-HT2A and 5-HT2C receptors as potential targets for modulation of psychostimulant use and dependence. Current Topics in Medicinal Chemistry 6 (2006) 1971-1985
23. Bubar M.J., and Cunningham K.A. Distribution of serotonin 5-HT2C receptors in the ventral tegmental area. Neuroscience 146 (2007) 286-297
24. Burmeister J.J., Lungren E.M., Kirschner K.F., and Neisewander J.L. Differential roles of 5-HT receptor subtypes in cue and cocaine reinstatement of cocaine-seeking behavior in rats. Neuropsychopharmacology 29 (2004) 660-668
25. Burmeister J.J., Lungren E.M., and Neisewander J.L. Effects of fluoxetine and d-fenfluramine on cocaine-seeking behavior in rats. Psychopharmacology 168 (2003) 146-154
26. Buydens-Branchey L., Branchey M., Hudson J., Rothman M., Fergeson P., and McKernin C. Effect of fenfluramine challenge on cocaine craving in addicted male users. American Journal on Addictions 7 (1998) 142-155
27. Carroll M.E., Lac S.T., Asencio M., and Kragh R. Fluoxetine reduces intravenous cocaine self-administration in rats. Pharmacology, Biochemistry and Behavior 35 (1990) 237-244
28. Celada P., Dolera M., Alvarez E., and Artigas F. Effects of acute and chronic treatment with fluvoxamine on extracellular and platelet serotonin in the blood of major depressive patients: Relationship to clinical improvement. Journal of Affective Disorders 25 (1992) 243-249
29. Connolly H.M., Crary J.L., McGoon M.D., Hensrud D.D., Edwards B.S., and Schaff H.V. Valvular heart disease associated with fenfluramine-phentermine. New England Journal of Medicine 337 (1997) 581-588
30. Connolly H.M., and McGoon M.D. Obesity drugs and the heart. Current Problems in Cardiology 24 (1999) 745-792
31. Cortijo J., Marti-Cabrera M., Bernabeu E., Domenech T., Bou J., Fernandez A.G., et al. Characterization of 5-HT receptors on human pulmonary artery and vein: Functional and binding studies. British Journal of Pharmacology 122 (1997) 1455-1463
32. Cozzi N.V., Frescas S., Marona-Lewicka D., Huang X., and Nichols D.E. Indan analogs of fenfluramine and norfenfluramine have reduced neurotoxic potential. Pharmacology, Biochemistry and Behavior 59 (1998) 709-715
33. Czoty P.W., Ginsburg B.C., and Howell L.L. Serotonergic attenuation of the reinforcing and neurochemical effects of cocaine in squirrel monkeys. Journal of Pharmacology and Experimental Therapeutics 300I (2002) 831-837
34. Dackis C.A., and Gold M.S. New concepts in cocaine addiction: The dopamine depletion hypothesis. Neuroscience and Biobehavioral Reviews 9 (1985) 469-477
35. Das G. Cocaine abuse in North America: A milestone in history. Journal of Clinical Pharmacology 33 (1993) 296-310
36. Das Y.T., Bagchi M., Bagchi D., and Preuss H.G. Safety of 5-hydroxy-L-tryptophan. Toxicology Letters 150 (2004) 111-122
37. Daw N.D., Kakade S., and Dayan P. Opponent interactions between serotonin and dopamine. Neural Network 15 (2002) 603-616
38. Di Chiara G., Bassareo V., Fenu S., De Luca M.A., Spina L., Cadoni C., et al. Dopamine and drug addiction: The nucleus accumbens shell connection. Neuropharmacology 47 Suppl 1 (2004) 227-241
39. Di Matteo V., De Blasi A., Di Giulio C., and Esposito E. Role of 5-HT(2C) receptors in the control of central dopamine function. Trends in Pharmacological Sciences 22 (2001) 229-232
40. Di Matteo V., Di Giovanni G., Di Mascio M., and Esposito E. SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system. Neuropharmacology 38 (1999) 1195-1205
41. Di Matteo V., Di Giovanni G., Di Mascio M., and Esposito E. Biochemical and electrophysiological evidence that RO 60-0175 inhibits mesolimbic dopaminergic function through serotonin (2C) receptors. Brain Research 865 (2000) 85-90
42. Droogmans, S., Cosyns, B., D'Haenen, H., Creeten, E., Weytjens, C., Franken, P. R., et al. (in press). Possible association between 3,4-Methylenedioxymethamphetamine abuse and valvular heart disease. American Journal of Cardiology
43. Eddahibi S., Fabre V., Boni C., Martres M.P., Raffestin B., Hamon M., et al. Induction of serotonin transporter by hypoxia in pulmonary vascular smooth muscle cells: Relationship with the mitogenic action of serotonin. Circulation Research 84 (1999) 329-336
44. Eddahibi S., Guignabert C., Barlier-Mur A.M., Dewachter L., Fadel E., Dartevelle P., et al. Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: Critical role for serotonin-induced smooth muscle hyperplasia. Circulation 113 (2006) 1857-1864
45. Eddahibi S., Humbert M., Fadel E., Raffestin B., Darmon M., Capron F., et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. Journal of Clinical Investigation 108 (2001) 1141-1150
46. Eriksson E., Engberg G., Bing O., and Nissbrandt H. Effects of mCPP on the extracellular concentrations of serotonin and dopamine in rat brain. Neuropsychopharmacology 20 (1999) 287-296
47. Filip M., and Cunningham K.A. Hyperlocomotive and discriminative stimulus effects of cocaine are under the control of serotonin(2C) (5-HT(2C)) receptors in rat prefrontal cortex. Journal of Pharmacology and Experimental Therapeutics 306 (2003) 734-743
48. Fishman A.P. Aminorex to fen/phen: An epidemic foretold. Circulation 99 (1999) 156-161
49. 2B receptors in the cardiopathy associated with fenfluramine. Molecular Pharmacology 57 (2000) 75-81
50. Fleckenstein A.E., Volz T.J., Riddle E.L., Gibb J.W., and Hanson G.R. New insights into the mechanism of action of amphetamines. Annual Review of Pharmacology and Toxicology 47 (2007) 681-698
51. Fletcher P.J., Chintoh A.F., Sinyard J., and Higgins G.A. Injection of the 5-HT2C receptor agonist Ro60-0175 into the ventral tegmental area reduces cocaine-induced locomotor activity and cocaine self-administration. Neuropsychopharmacology 29 (2004) 308-318
52. Fletcher P.J., Grottick A.J., and Higgins G.A. Differential effects of the 5-HT(2A) receptor antagonist M100907 and the 5-HT(2C) receptor antagonist SB242084 on cocaine-induced locomotor activity, cocaine self-administration and cocaine-induced reinstatement of responding. Neuropsychopharmacology 27 (2002) 576-586
53. Gaine S.P., Rubin L.J., Kmetzo J.J., Palevsky H.I., and Traill T.A. Recreational use of aminorex and pulmonary hypertension. Chest 118 (2000) 1496-1497
54. Garlow S.J., Purselle D., and D'Orio B. Cocaine use disorders and suicidal ideation. Drug and Alcohol Dependence 70 (2003) 101-104
55. Gawin F.H., and Kleber H.D. Abstinence symptomatology and psychiatric diagnosis in cocaine abusers. Archives of General Psychiatry 43 (1986) 107-113
56. Ghitza U.E., Rothman R.B., Gorelick D.A., Henningfield J.E., and Baumann M.H. Serotonergic responsiveness in human cocaine users. Drug and Alcohol Dependence 86 (2007) 207-213
57. Glatz A.C., Ehrlich M., Bae R.S., Clarke M.J., Quinlan P.A., Brown E.C., et al. Inhibition of cocaine self-administration by fluoxetine or D-fenfluramine combined with phentermine. Pharmacology, Biochemistry and Behavior 71 (2002) 197-204
58. Glowa J.R., Rice K.C., Matecka D., and Rothman R.B. Phentermine/fenfluramine decreases cocaine self-administration in rhesus monkeys. Neuroreport 8 (1997) 1347-1351
59. Glowa J.R., Wojnicki F.H.E., Matecka D., Rice K.C., and Rothman R.B. Effects of dopamine reuptake inhibitors on food- and cocaine-maintained responding: II. Comparisons with other drugs and repeated administrations. Experimental and Clinical Psychopharmacology 3 (1995) 232-239
60. Gobert A., Rivet J.M., Lejeune F., Newman-Tancredi A., Adhumeau-Auclair A., Nicolas J.P., et al. Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat. Synapse 36 (2000) 205-221
61. Gonzalez Castro F., Barrington E.H., Walton M.A., and Rawson R.A. Cocaine and methamphetamine: Differential addiction rates. Psychology of Addictive Behaviors 14 (2000) 390-396
62. Gorelick D.A. The rate hypothesis and agonist substitution approaches to cocaine abuse treatment. Advances in Pharmacology 42 (1998) 995-997
63. Grabowski J., Rhoades H., Schmitz J., Stotts A., Daruzska L.A., Creson D., et al. Dextroamphetamine for cocaine-dependence treatment: A double-blind randomized clinical trial. Journal of Clinical Psychopharmacology 21 (2001) 522-526
64. Grabowski J., Rhoades H., Stotts A., Cowan K., Kopecky C., Dougherty A., et al. Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: Two double-blind randomized clinical trials. Neuropsychopharmacology 29 (2004) 969-981
65. Grabowski J., Roache J.D., Schmitz J.M., Rhoades H., Creson D., and Korszun A. Replacement medication for cocaine dependence: Methylphenidate. Journal of Clinical Psychopharmacology 17 (1997) 485-488
66. Grabowski J., Shearer J., Merrill J., and Negus S.S. Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addictive Behaviors 29 (2004) 1439-1464
67. Greenhill L.L. The science of stimulant abuse. Pediatric Annals 35 (2006) 552-556
68. Grottick A.J., Fletcher P.J., and Higgins G.A. Studies to investigate the role of 5-HT(2C) receptors on cocaine- and food-maintained behavior. Journal of Pharmacology and Experimental Therapeutics 295 (2000) 1183-1191
69. Gurtner H.P. Aminorex and pulmonary hypertension. Cor et Vasa 27 (1985) 160-171
70. Gustafsson B.I., Tommeras K., Nordrum I., Loennechen J.P., Brunsvik A., Solligard E., et al. Long-term serotonin administration induces heart valve disease in rats. Circulation 111 (2005) 1517-1522
71. Hafizi S., Taylor P.M., Chester A.H., Allen S.P., and Yacoub M.H. Mitogenic and secretory responses of human valve interstitial cells to vasoactive agents. Journal of Heart Valve Disease 9 (2000) 454-458
72. Halladay A.K., Kirschner E., Hesse K., Fisher H., and Wagner G.C. Role of monoamine oxidase inhibition and monoamine depletion in fenfluramine-induced neurotoxicity and serotonin release. Pharmacology and Toxicology 89 (2001) 237-248
73. Halladay A.K., Wagner G.C., Hsu T., Sekowski A., and Fisher H. Differential effects of monoaminergic agonists on alcohol intake in rats fed a tryptophan-enhanced diet. Alcohol 18 (1999) 55-64
74. Halladay A.K., Wagner G.C., Sekowski A., Rothman R.B., Baumann M.H., and Fisher H. Alterations in alcohol consumption, withdrawal seizures, and monoamine transmission in rats treated with phentermine and 5-hydroxy-L-tryptophan. Synapse 59 (2006) 277-289
75. Haney M., Ward A.S., Gerra G., and Foltin R.W. Neuroendocrine effects of d-fenfluramine and bromocriptine following repeated smoked cocaine in humans. Drug and Alcohol Dependence 64 (2001) 63-73
76. Hendrikx M., Van Dorpe J., Flameng W., and Daenen W. Aortic and mitral valve disease induced by ergotamine therapy for migraine: A case report and review of the literature. Journal of Heart Valve Disease 5 (1996) 235-237
77. Henningfield J.E. Nicotine medications for smoking cessation. New England Journal of Medicine 333 (1995) 1196-1203
78. Herve P., Launay J.-M., Scrobohaci M.-L., Brenot F., Simonneau G., Petitpretz P., et al. Increased plasma serotonin in primary pulmonary hypertension. American Journal of Medicine 99 (1995) 249-254
79. Higgins G.A., and Fletcher P.J. Serotonin and drug reward: Focus on 5-HT2C receptors. European Journal of Pharmacology 480 (2003) 151-162
80. Howell L.L., and Byrd L.D. Serotonergic modulation of the behavioral effects of cocaine in the squirrel monkey. Journal of Pharmacology and Experimental Therapeutics 275 (1995) 1551-1559
81. Howell L.L., Carroll F.I., Votaw J.R., Goodman M.M., and Kimmel H.L. Effects of combined dopamine and serotonin transporter inhibitors on cocaine self-administration in rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics 320 (2007) 757-765
82. Hoyer D., Clarke D.E., Fozard J.R., Hartig P.R., Martin G.R., Mylecharane E.J., et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacological Reviews 46 (1994) 157-203
83. Hoyer D., Hannon J.P., and Martin G.R. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacology, Biochemistry and Behavior 71 (2002) 533-554
84. Hyman S.E. Addiction: A disease of learning and memory. American Journal of Psychiatry 162 (2005) 1414-1422
85. Ishida M., Otani K., Kaneko S., Ohkubo T., Osanai T., Yasui N., et al. Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. International Clinical Psychopharmacology 10 (1995) 143-146
86. Iversen L. Neurotransmitter transporters and their impact on the development of psychopharmacology. British Journal of Pharmacology 147 Suppl 1 (2006) S82-88
87. Kalivas P.W., and O'Brien C. Drug addiction as a pathology of staged neuroplasticity. Neuropsychopharmacology 33 (2008) 166-180
88. Kampman K.M., Rukstalis M., Pettinati H., Muller E., Acosta T., Gariti P., et al. The combination of phentermine and fenfluramine reduced cocaine withdrawal symptoms in an open trial. Journal of Substance Abuse Treat 19 (2000) 77-79
89. Koob G.F. Alcoholism: Allostasis and beyond. Alcoholism, Clinical and Experimental Research 27 (2003) 232-243
90. Koob G.F., Roberts A.J., Schulteis G., Parsons L.H., Heyser C.J., Hyytia P., et al. Neurocircuitry targets in ethanol reward and dependence. Alcoholism, Clinical and Experimental Research 22 (1998) 3-9
91. Launay J.M., Herve P., Peoc'h K., Tournois C., Callebert J., Nebigil C.G., et al. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nature Medicine 8 (2002) 1129-1135
92. Lesch K.P. Alcohol dependence and gene × environment interaction in emotion regulation: Is serotonin the link?. European Journal of Pharmacology 526 (2005) 113-124
93. Levy A.D., Li Q., and Van de Kar L.D. Repeated cocaine exposure inhibits the adrenocorticotropic hormone response to the serotonin releaser d-fenfluramine and the 5-HT1A agonist, 8-OH-DPAT. Neuropharmacology 33 (1994) 335-342
94. Lile J.A. Pharmacological determinants of the reinforcing effects of psychostimulants: Relation to agonist substitution treatment. Experimental and Clinical Psychopharmacology 14 (2006) 20-33
95. Lin D., Koob G.F., and Markou A. Differential effects of withdrawal from chronic amphetamine or fluoxetine administration on brain stimulation reward in the rat-interactions between the two drugs. Psychopharmacology 145 (1999) 283-294
96. Ling W., Rawson R.A., and Compton M.A. Substitution pharmacotherapies for opioid addiction: From methadone to LAAM and buprenorphine. Journal of Psychoactive Drugs 26 (1994) 119-128
97. Liu S., Bubar M.J., Lanfranco M.F., Hillman G.R., and Cunningham K.A. Serotonin2C receptor localization in GABA neurons of the rat medial prefrontal cortex: Implications for understanding the neurobiology of addiction. Neuroscience 146 (2007) 1677-1688
98. Lopez-Ilasaca M. Signaling from G-protein-coupled receptors to mitogen-activated protein (MAP)-kinase cascades. Biochemical Pharmacology 56 (1998) 269-277
99. Lundmark J., Reis M., and Bengtsson F. Serum concentrations of fluoxetine in the clinical treatment setting. Therapeutic Drug Monitoring 23 (2001) 139-147
100. MacLean M.R., Herve P., Eddahibi S., and Adnot S. 5-hydroxytryptamine and the pulmonary circulation: Receptors, transporters and relevance to pulmonary arterial hypertension. British Journal of Pharmacology 131 (2000) 161-168
101. Mann J.J. Neurobiology of suicidal behaviour. Nature Reviews: Neuroscience 4 (2003) 819-828
102. Marcos E., Adnot S., Pham M.H., Nosjean A., Raffestin B., Hamon M., et al. Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine 168 (2003) 487-493
103. Markou A., and Koob G.F. Postcocaine anhedonia: An animal model of cocaine withdrawal. Neuropsychopharmacology 4 (1991) 17-26
104. Martin F., and Artigas F. Simultaneous effects of p-chloroamphetamine, d-fenfluramine, and reserpine on free and stored 5-hydroxytryptamine in brain and blood. Journal of Neurochemistry 59 (1992) 1138-1144
105. Martinez D., Narendran R., Foltin R.W., Slifstein M., Hwang D.R., Broft A., et al. Amphetamine-induced dopamine release: Markedly blunted in cocaine dependence and predictive of the choice to self-administer cocaine. American Journal of Psychiatry 164 (2007) 622-629
106. Masson J., Sagne C., Hamon M., and el Mestikawy S. Neurotransmitter transporters in the central nervous system. Pharmacological Reviews 51 (1999) 439-464
107. McCann U.D., Seiden L.S., Rubin L.J., and Ricaurte G.A. Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine: A systematic review of the evidence. Journal of the American Medical Association 278 (1997) 666-672
108. McGregor A., Lacosta S., and Roberts D.C. L-tryptophan decreases the breaking point under a progressive ratio schedule of intravenous cocaine reinforcement in the rat. Pharmacology, Biochemistry and Behavior 44 (1993) 651-655
109. Mogenson G.J., Jones D.L., and Yim C.Y. From motivation to action: Functional interface between the limbic system and the motor system. Progress in Neurobiology 14 (1980) 69-97
110. Molliver M.E. Serotonergic neuronal systems: What their anatomic organization tells us about function. Journal of Clinical Psychopharmacology 7 Suppl 6 (1987) 3S-23S
111. Moore R.Y., and Bloom F.E. Central catecholamine neuron systems: Anatomy and physiology of the dopamine systems. Annual Review of Neuroscience 1 (1978) 129-169
112. Muller C.P., and Huston J.P. Determining the region-specific contributions of 5-HT receptors to the psychostimulant effects of cocaine. Trends in Pharmacological Sciences 27 (2006) 105-112
113. Musto D.F. Cocaine's history, especially the American experience. Ciba Foundation Symposium 166 (1992) 7-14
114. Negus S.S., and Mello N.K. Effects of chronic d-amphetamine treatment on cocaine- and food-maintained responding under a progressive-ratio schedule in rhesus monkeys. Psychopharmacology 167 (2003) 324-332
115. Negus S.S., and Mello N.K. Effects of chronic d-amphetamine treatment on cocaine- and food-maintained responding under a second-order schedule in rhesus monkeys. Drug and Alcohol Dependence 70 (2003) 39-52
116. Negus S.S., Mello N.K., Blough B.E., Baumann M.H., and Rothman R.B. Monoamine releasers with varying selectivity for dopamine/norepinephrine versus serotonin release as candidate "agonist" medications for cocaine dependence: Studies in assays of cocaine discrimination and cocaine self-administration in rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics 320 (2007) 627-636
117. Negus S.S., Mello N.K., Blough B.E., Baumann M.H., and Rothman R.B. Monoamine releasers with varying selectivity for dopamine/norepinephrine versus serotonin release as candidate "agonist" medications for cocaine dependence: Studies in assays of cocaine discrimination and cocaine self-administration in rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics 320 (2007) 627-636
118. Nemecek G.M., Coughlin S.R., Handley D.A., and Moskowitz M.A. Stimulation of aortic smooth muscle cell mitogenesis by serotonin. Proceedings of the National Academy of Sciences of the United States of America 83 (1986) 674-678
119. Ni W., and Watts S.W. 5-hydroxytryptamine in the cardiovascular system: Focus on the serotonin transporter (SERT). Clinical and Experimental Pharmacology and Physiology 33 (2006) 575-583
120. Nichols D.E., Brewster W.K., Johnson M.P., Oberlender R., and Riggs R.M. Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA). Journal of Medicinal Chemistry 33 (1990) 703-710
121. Nilsson B.M. 5-Hydroxytryptamine 2C (5-HT2C) receptor agonists as potential antiobesity agents. Journal of Medicinal Chemistry 49 (2006) 4023-4034
122. Otani K., Mihara K., Yasui N., Ishida M., Kondo T., Tokinaga N., et al. Plasma concentrations of trazodone and m-chlorophenylpiperazine at steady state can be predicted from those after an initial dose of trazodone. Progress in Neuro-Psychopharmacology and Biological Psychiatry 21 (1997) 239-244
123. Parsons L.H., Koob G.F., and Weiss F. Serotonin dysfunction in the nucleus accumbens of rats during withdrawal after unlimited access to intravenous cocaine. Journal of Pharmacology and Experimental Therapeutics 274 (1995) 1182-1191
124. Parsons L.H., Smith A.D., and Justice Jr. J.B. Basal extracellular dopamine is decreased in the rat nucleus accumbens during abstinence from chronic cocaine. Synapse 9 (1991) 60-65
125. Pennartz C.M., Groenewegen H.J., and Lopes da Silva F.H. The nucleus accumbens as a complex of functionally distinct neuronal ensembles: An integration of behavioural, electrophysiological and anatomical data. Progress in Neurobiology 42 (1994) 719-761
126. Pitt B.R., Weng W., Steve A.R., Blakely R.D., Reynolds I., and Davies P. Serotonin increases DNA synthesis in rat proximal and distal pulmonary vascular smooth muscle cells in culture. American Journal of Physiology 266 (1994) L178-L186
127. 2C receptors in CHO-K1 cells. British Journal of Pharmacology 128 (1999) 13-20
128. Rea W.P., Rothman R.B., and Shippenberg T.S. Evaluation of the conditioned reinforcing effects of phentermine and fenfluramine in the rat: Concordance with clinical studies. Synapse 30 (1998) 107-111
129. Roberts D.C., Phelan R., Hodges L.M., Hodges M.M., Bennett B., Childers S., et al. Self-administration of cocaine analogs by rats. Psychopharmacology 144 (1999) 389-397
130. Rollema H., Coe J.W., Chambers L.K., Hurst R.S., Stahl S.M., and Williams K.E. Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation. Trends in Pharmacological Sciences 28 (2007) 316-325
131. Rose S., Hunt S., Collins P., Hindmarsh J.G., and Jenner P. Repeated administration of escalating high doses of dexfenfluramine does not produce morphological evidence for neurotoxicity in the cortex of rats. Neurodegeneration 5 (1996) 145-152
132. Rossetti Z.L., Hmaidan Y., and Gessa G.L. Marked inhibition of mesolimbic dopamine release: A common feature of ethanol, morphine, cocaine and amphetamine abstinence in rats. European Journal of Pharmacology 221 (1992) 227-234
133. Roth B.L. Drugs and valvular heart disease. New England Journal of Medicine 356 (2007) 6-9
134. Rothman, R. B. (in press). Treatment of obesity with "combination" pharmacotherapy. American Journal of Therapeutics
135. Rothman R.B., Ayestas M.A., Dersch C.M., and Baumann M.H. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates: Implications for primary pulmonary hypertension. Circulation 100 (1999) 869-875
136. Rothman R.B., and Baumann M. Therapeutic and adverse actions of serotonin transporter substrates. Pharmacology and Therapeutics 95 (2002) 73-88
137. Rothman R.B., and Baumann M.H. Monoamine transporters and psychostimulant drugs. European Journal of Pharmacology 479 (2003) 23-40
138. Rothman R.B., and Baumann M.H. Therapeutic potential of monoamine transporter substrates. Current Topics in Medicinal Chemistry 6 (2006) 1845-1859
139. Rothman R.B., Baumann M.H., Dersch C.M., Romero D.V., Rice K.C., Carroll F.I., et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39 (2001) 32-41
140. 2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102 (2000) 2836-2841
141. Rothman R.B., Blough B.E., and Baumann M.H. Appetite suppressants as agonist substitution therapies for stimulant dependence. Annals of the New York Academy of Sciences 965 (2002) 109-126
142. Rothman R.B., Blough B.E., and Baumann M.H. Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions. The AAPS Journal 9 (2007) E1-E10
143. Rothman R.B., Blough B.E., Woolverton W.L., Anderson K.G., Negus S.S., Mello N.K., et al. Development of a rationally-designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration. Journal of Pharmacology and Experimental Therapeutics 313 (2005) 1361-1369
144. Rothman R.B., Clark R.D., Partilla J.S., and Baumann M.H. (+)-Fenfluramine and its major metabolite, (+)-norfenfluramine, are potent substrates for norepinephrine transporters. Journal of Pharmacology and Experimental Therapeutics 305 (2003) 1191-1199
145. Rothman R.B., Elmer G.I., Shippenberg T.S., Rea W., and Baumann M.H. Phentermine and fenfluramine: Preclinical studies in animal models of cocaine addiction. Annals of the New York Academy of Sciences 844 (1998) 59-74
146. Rothman R.B., Gendron T.M., and Hitzig P. Combined use of fenfluramine and phentermine in the treatment of cocaine addiction: A pilot case series. Journal of Substance Abuse Treatment 11 (1994) 273-275
147. Rothman R.B., Jayanthi S., Wang X., Dersch C.M., Cadet J.L., Prisinzano T., et al. High-dose fenfluramine administration decreases serotonin transporter binding, but not serotonin transporter protein levels, in rat forebrain. Synapse 50 (2003) 233-239
148. Rothman R.B., Redmon J.B., Raatz S.K., Kwong C.A., Swanson J.E., and Bantle J.P. Chronic treatment with the phentermine combined with fenfluramine lowers plasma serotonin. American Journal of Cardiology 85 (2000) 913-915
149. Rudnick G. Mechanisms of biogenic amine transporters. In: Reith M.E.A. (Ed). Neurotransmitter transporters: Structure, function and regulation (1997), Humana Press, Totowa, NJ 73-100
150. Sachdev M., Miller W.C., Ryan T., and Jollis J.G. Effect of fenfluramine-derivative diet pills on cardiac valves: A meta-analysis of observational studies. American Heart Journal 144 (2002) 1065-1073
151. Setola V., Hufeisen S.J., Grande-Allen K.J., Vesely I., Glennon R.A., Blough B., et al. 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Molecular Pharmacology 63 (2003) 1223-1229
152. Setola V., and Roth B.L. Screening the receptorome reveals molecular targets responsible for drug-induced side effects: Focus on "fen-phen.". Expert Opinion on Drug Metabolism and Toxicology 1 (2005) 377-387
153. Seuwen K., Magnaldo I., and Pouyssegur J. Serotonin stimulates DNA synthesis in fibroblasts acting through 5-HT1B receptors coupled to a Gi-protein. Nature 335 (1988) 254-256
154. Shearer J., Wodak A., van Beek I., Mattick R.P., and Lewis J. Pilot randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence. Addiction 98 (2003) 1137-1141
155. Sitte H.H., and Freissmuth M. Oligomer formation by Na+-Cl-coupled neurotransmitter transporters. European Journal of Pharmacology 479 (2003) 229-236
156. Smith F.L., Yu D.S., Smith D.G., Leccese A.P., and Lyness W.H. Dietary tryptophan supplements attenuate amphetamine self-administration in the rat. Pharmacology, Biochemistry and Behavior 25 (1986) 849-855
157. Steinbusch H.W. Distribution of serotonin-immunoreactivity in the central nervous system of the rat-cell bodies and terminals. Neuroscience 6 (1981) 557-618
158. Steranka L.R., and Sanders-Bush E. Long-term effects of fenfluramine on central serotonergic mechanisms. Neuropharmacology 18 (1979) 895-903
159. Sulzer D., Sonders M.S., Poulsen N.W., and Galli A. Mechanisms of neurotransmitter release by amphetamines: A review. Progress in Neurobiology 75 (2005) 406-433
160. Torres G.E., and Amara S.G. Glutamate and monoamine transporters: New
161. Uhl G.R., and Johnson P.S. Neurotransmitter transporters: Three important gene families for neuronal function. Journal of Experimental Biology 196 (1994) 229-236
162. Ungerstedt U. Stereotaxic mapping of the monoamine pathways in the rat brain. Acta Physiologica Scandinavica Supplement 367 (1971) 1-48
163. Vickers S.P., Clifton P.G., Dourish C.T., and Tecott L.H. Reduced satiating effect of d-fenfluramine in serotonin 5-HT(2C) receptor mutant mice. Psychopharmacology 143 (1999) 309-314
164. Volkow N.D., Fowler J.S., and Wang G.J. Role of dopamine in drug reinforcement and addiction in humans: Results from imaging studies. Behavioural Pharmacology 13 (2002) 355-366
165. Volkow N.D., and Li T.K. Drug addiction: The neurobiology of behaviour gone awry. Nature Reviews: Neuroscience 5 (2004) 963-970
166. Volkow N.D., Wang G.J., Fowler J.S., Logan J., Gatley S.J., Hitzemann R., et al. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 386 (1997) 830-833
167. Walsh S.L., Haberny K.A., and Bigelow G.E. Modulation of intravenous cocaine effects by chronic oral cocaine in humans. Psychopharmacology 150 (2000) 361-373
168. Wee S., Anderson K.G., Baumann M.H., Rothman R.B., Blough B.E., and Woolverton W.L. Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs. Journal of Pharmacology and Experimental Therapeutics 313 (2005) 848-854
169. Weiss F., Parsons L.H., Schulteis G., Hyytia P., Lorang M.T., Bloom F.E., et al. Ethanol self-administration restores withdrawal-associated deficiencies in accumbal dopamine and 5-hydroxytryptamine release in dependent rats. Journal of Neuroscience 16 (1996) 3474-3485
170. White J.M., and Lopatko O.V. Opioid maintenance: A comparative review of pharmacological strategies. Expert Opin Pharmacother 8 (2007) 1-11
171. Wojnicki F.H.E., Rothman R.B., Rice K.C., and Glowa J.R. Effects of phentermine on responding maintained under multiple fixed-ratio schedules of food-presentation and cocaine-delivery in the rhesus monkey. Journal of Pharmacology and Experimental Therapeutics 288 (1999) 550-560
172. Yu Y.L., Fisher H., Sekowski A., and Wagner G.C. Amphetamine and fenfluramine suppress ethanol intake in ethanol-dependent rats. Alcohol 14 (1997) 45-48
173. Zaczek R., Battaglia G., Culp S., Appel N.M., Contrera J.F., and De Souza E.B. Effects of repeated fenfluramine administration on indices of monoamine function in rat brain: Pharmacokinetic, dose response, regional specificity and time course data. Journal of Pharmacology and Experimental Therapeutics 253 (1990) 104-112
174. Zolkowska D., Rothman R.B., and Baumann M.H. Amphetamine analogs increase plasma serotonin: Implications for cardiac and pulmonary disease. Journal of Pharmacology and Experimental Therapeutics 318 (2006) 604-610
175. Zolkowska D., Baumann M.H., and Rothman R.B. Chronic fenfluramine administration increases plasma serotonin (5-HT) to non-toxic levels. Journal of Pharmacology and Experimental Therapeutics 324 (2008) 791-797